Association between CCR5 genotype and the clinical course of HIV-1 infection

Annals of Internal Medicine

Volumn 127, Issue 10, 1997, Pages 882-890

  De Roda Husman, Ana Maria ^a   Koot, Maarten ^a   Cornelissen, Marion ^b   Keet, Ireneus P M ^c   Brouwer, Margreet ^a   Broersen, Silvia M ^a   Bakker, Margreet ^b   Roos, Marijke T L ^a   Prins, Maria ^c   De Wolf, Frank ^b   Coutinho, Roel A ^c   Miedema, Frank ^a   Goudsmit, Jaap ^b   Schuitemaker, Hanneke ^a  

^a CENTRAL LABORATORY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MUNICIPAL HEALTH SERVICE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; GENE DELETION; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL;

EID: 0007643930     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-10-199711150-00004     Document Type: Article

References (41)

1. Mellors JW. Rinaldo CR Gupta P. White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996:272:1167-70.
2. + T cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS. [In press].
3. Tersmette M, Gruters RA, de Wolf F, de Goede RE, Lange JM, Schellekens PT, et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol. 1989;63:2118-25.
4. + cell depletion and progression to AIDS. Ann Intern Med. 1993;118:681-8.
5. + T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected infected individuals. J Virol. 1993;67:1772-7.
6. Roos MT, Miedema f, Koot M. Tersmette M, Schaasberg WP. Coutinho RA, et al. T cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus-infected asymptomatic subjects. J Infect Dis. 1995:171:531-6.
7. Kaslow RA, Duquesnoy R, VanRaden M, Kingsley L, Marrari M, Friedman H, et al. AI, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study. Lancet. 1990:335:927-30.
8. Klein MR, Keet IP, D'Amaro J, Bende RJ. Hekman A, Mesman B, et al. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J Infect Dis. 1994; 169:1244-9.
9. Miedema F, Meyaard L, Koot M, Klein MR, Roos MT, Groenink M. et al. Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev. 1994;140:35-72.
10. Deng HK, Liu R. Ellmeier W. Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996:381:661-6.
11. + cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996:381:667-73.
12. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES, MIP-1a, MIP-1/3 receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996:272:1955-8.
13. Choe H, Farzan M, Sun Y, Sullivan M, Rollins B, Ponath PD, et al. The 0-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996:85:1135-48.
14. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the /3-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 1996;85:1149-58.
15. Zhang L, Huang Y, He T, Cao Y, Ho DD. HIV-1 subtype and secondreceptor use [Letter]. Nature. 1996;383:768.
16. Simmons G, Wilkinson D, Reeves JD, Dittmar MT, Beddows S, Weber J, et al. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as co-receptors for virus entry. J Virol. 1996:70:8355-60.
17. Samson M, Libert F, Doranz BJ, Rucker J, Liesnord C, Farber CM, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996:382:722-5.
18. Liu R, Paxton WA, Choe S, Ceradini D. Martin SR. Horuk R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996:86:367-77.
19. Zhu T. Mo H, Wang N, Nam DS, Cao Y, Koup RA, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science. 1993:261:1179-81.
20. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpbier HJ, Veenstra J, et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest. 1994;94:2060-7.
21. Dean M, Carrington M, Winkler C. Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 1996:273:1856-62.
22. Eugen-Olsen J, Iversen AK, Garred P, Koppelhus U, Pedersen C, Benfield TL, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS. 1997;11:305-10.
23. Michael ML, Chang G, Louie LG, Mascola JR, Dondero D, Birx DU et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nature Medicine. 1997:3:338-40.
24. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med. 1997;3:23-36.
25. + cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis. 1988:158:615-'22.
26. van Griensven GJ, de Vroome EM, Goudsmit J, Coutinho RA. Changes in sexual behaviour and the fall in incidence of HIV infection among homosexual men. BMJ. 1989:298:218-21.
27. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep. 1987; 36(Suppl 1):1S-15S.
28. Tersmette M. de Goede RE. AI BJ, Winkel IN, Gruters RA, Cuypers HT, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol. 1988:62:2026-32.
29. Koot M. Vos AH, Keet RP, de Goede RE, Dercksen MW, Terpstra FG, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS. 1992:6:49-54.
30. van Gemen B, van Beuningen R, Nabbe A, van Strijp D, Jurriaans S, Lens P, et al. A one-tube quantitative HIV-1 RNA NASBA nucleic add amplification assay using electrochemiluminescent (ECL) labelled probes. J Virol Methods. 1994;49:157-67.
31. Bloemena E, Roos MT, van Heijst JL, Vossen JM, Schellekens P. Wholeblood lymphocyte cultures. J Immunol Methods. 1989:122:161-7.
32. Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978:8:283-98.
33. Huang Y, Paxton WA, Wolinsky SM, Neumann AD, Zhang L, He T, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Medicine. 1996:2:1240-3.
34. Phillips AN. Studies of prognostic-markers in HIV infection: implications for pathogenesis. AIDS. 1992:6:1391-4.
35. Faucett CL, Thomas DC. Simultaneously modelling censored survival data and repeatedly measured co-variates: a Gibbs sampling approach. Stat Med. 1996:15:1663-85.
36. De Gruttola V, Tu XM. Modelling progression of CD4-lymphocyte count and its relationship to survival time. Biometrics. 1997;50:1003-14.
37. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol. 1992:66:3183-7.
38. Groenink M, Fouchier RA, Broersen S, Naker CH, Koot M, van't Woot AB. et al. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science. 1993:260:1513-6.
39. Fouchier RA, Broersen SM, Brouwer M, Tersmette M, Van't Wout AB, Groenink M, et al. Temporal relationship between elongation of the HIV-1 type 1 glycoprotein 120 V2 domain and the conversion toward a syncytiuminducing phenotype. AIDS Res Hum Retroviruses. 1995;l 1:1473-8.
40. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol. 1992;66:1354-60.
41. Koot M. van 't Wout AB, Kootstra NA, de Goede RE, Tersmette M, Schuitemaker H. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis. 1996;173: 349-54.